Competition for IMU?, page-25

PD1vaxx has ONE complete response with some SDs and PRs. However, I am sure upon further investigation, that patient with complete response probably has a particular mutation that is highly treatable by PD1vaxx. So if IMU were to now find this subset of patients with this particular NSCLC mutation, PD1vaxx will also very likely achieve 100% CR.

At end of day, cancer is not an easy disease to treat due to its many possible mutation. A single patient could even have several different mutation of a disease. This is precisely why Leslie Chong have been advocating the advancement of combination treatments like PD1vaxx/Tecentriq, Hervaxx/Keytruda and even CF33/Keytruda. More complex combination might even be required for more complex cases.

However, at least it is most joyful to learn that this particular rectal cancer subset has a cure now. Soon, other subset will also find its own cure. Then a combination treatment would be able to deal with both subsets and so on. It is a really, really good start. What's more, it validates the viability of immunotherapy.